Cargando…

Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance

OBJECTIVE: The purpose of this study is to develop an anti-PDL1-based interferon (IFN) fusion protein to overcome the chronic hepatitis B virus (HBV)-induced immune tolerance, and combine this immunotherapy with a HBV vaccine to achieve the functional cure of chronic hepatitis B (CHB) infection. DES...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meng, Chao-Yang, Sun, Shiyu, Liang, Yong, Xu, Hairong, Zhang, Chao, Zhang, Min, Wang, Fu-Sheng, Fu, Yang-Xin, Peng, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359590/ https://www.ncbi.nlm.nih.gov/pubmed/36316098 http://dx.doi.org/10.1136/gutjnl-2022-327059

Ejemplares similares

Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection
por: Murata, Kazumoto, et al.
Publicado: (2018)

Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients
por: Zhang, Chao, et al.
Publicado: (2023)

Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B
por: Svicher, Valentina, et al.
Publicado: (2021)

PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF
por: Li, Jiang, et al.
Publicado: (2022)

Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection
por: Li, Haijun, et al.
Publicado: (2018)

Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas
por: Amaddeo, Giuliana, et al.
Publicado: (2015)

HBV infection-induced liver cirrhosis development in dual-humanised mice with human bone mesenchymal stem cell transplantation
por: Yuan, Lunzhi, et al.
Publicado: (2019)

TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection
por: Heim, Kathrin, et al.
Publicado: (2021)

Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection
por: Aliabadi, Elmira, et al.
Publicado: (2022)

Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo
por: Allweiss, Lena, et al.
Publicado: (2022)

Quantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cure
por: Allweiss, Lena, et al.
Publicado: (2023)

TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice
por: Martin, Perrine, et al.
Publicado: (2015)

The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa
por: Lemoine, Maud, et al.
Publicado: (2016)

Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro
por: Rossi, Marzia, et al.
Publicado: (2023)

Cell-based cccDNA reporter assay combined with functional genomics identifies YBX1 as HBV cccDNA host factor and antiviral candidate target
por: Verrier, Eloi R, et al.
Publicado: (2023)

Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection
por: Janssen, Harry L A, et al.
Publicado: (2023)

Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance
por: Sun, Nannan, et al.
Publicado: (2021)

Association between lymphocyte-to-monocyte ratio (LMR) and the mortality of HBV-related liver cirrhosis: a retrospective cohort study
por: Zhang, Jie, et al.
Publicado: (2015)

STK33 promotes hepatocellular carcinoma through binding to c-Myc
por: Yang, Tian, et al.
Publicado: (2016)

Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections
por: Burm, Rani, et al.
Publicado: (2023)

STAT4-associated natural killer cell tolerance following liver transplantation
por: Jamil, K M, et al.
Publicado: (2017)

Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis
por: Nguyen, Nghia H, et al.
Publicado: (2016)

SENP1 promotes hypoxia-induced cancer stemness by HIF-1α deSUMOylation and SENP1/HIF-1α positive feedback loop
por: Cui, Chun-Ping, et al.
Publicado: (2017)

Gender differences in demographic and clinical characteristics in patients with HBV-related liver diseases in China
por: Liu, Mei, et al.
Publicado: (2022)

Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites
por: Zhang, Xiang, et al.
Publicado: (2021)

Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD
por: Montagner, Alexandra, et al.
Publicado: (2016)

Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein
por: Sautto, Giuseppe A, et al.
Publicado: (2016)

A new model predicts hepatocellular carcinoma in patients with HBV-related decompensated liver cirrhosis and long-term antiviral therapy: a prospective study
por: Mao, Hao-dan, et al.
Publicado: (2023)

Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression
por: Loyer, Xavier, et al.
Publicado: (2016)

Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas
por: Zhang, Qi, et al.
Publicado: (2019)

From clinical variables to multiomics analysis: a margin morphology-based gross classification system for hepatocellular carcinoma stratification
por: Fan, Zhongqi, et al.
Publicado: (2023)

The paradox of NKp46(+) natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon α treatment
por: Pembroke, Tom, et al.
Publicado: (2014)

Prevalence and clinical correlates of insomnia symptoms and their association with quality of life in Chinese patients with HBV-related liver disease
por: Zhao, Jing, et al.
Publicado: (2021)

Tenofovir alafenamide fumarate therapy in subjects with positive HBV-DNA and normal levels of alanine transaminase: a study protocol for a randomised controlled trial
por: Wang, Lu, et al.
Publicado: (2021)

Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene
por: Watanabe, Tsunamasa, et al.
Publicado: (2013)

Hepatic overexpression of cAMP-responsive element modulator α induces a regulatory T-cell response in a murine model of chronic liver disease
por: Kuttkat, Nadine, et al.
Publicado: (2017)

Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study
por: Kimura, Masamichi, et al.
Publicado: (2022)

Molecular mechanism of albumin in suppressing invasion and metastasis of hepatocellular carcinoma
por: Fu, Xiao, et al.
Publicado: (2021)

Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma
por: Cai, Jiabin, et al.
Publicado: (2019)

SIRT1-dependent mechanisms and effects of resveratrol for amelioration of muscle wasting in NASH mice
por: Liu, Chih-Wei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pla5nl7mbvako1bu2np6st76dd